Cysteinyl-leukotriene, receptor antagonist prevents urological cancer cell growth through early apoptosis

被引：0

作者：

Matsuyama, Masahide ^{[1
]}

Funao, Kiyoaki ^{[1
]}

Kuratukuri, Katsuyuki ^{[1
]}

Tanaka, Tomoaki ^{[1
]}

Kawahito, Yutaka ^{[2
]}

Sano, Hajime ^{[4
]}

Yoshimura, Norio ^{[3
]}

Nakatani, Tatsuya ^{[1
]}

Yoshimura, Rikio ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Urol, Osaka 5458585, Japan

[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Inflammat & Immunol, Kyoto 6020841, Japan

[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Transplantat & Regenerat Surg, Kyoto 6020841, Japan

[4] Hyogo Coll Med, Dept Internal Med, Kobe, Hyogo 6638501, Japan

来源：

MOLECULAR MEDICINE REPORTS | 2010年 / 3卷 / 02期

关键词：

cysteinyl-leukotriene; receptor antagonist; urological cancer cells; apoptosis;

D O I：

10.3892/mmr_0000261

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent Studies have demonstrated that the cysteinyl-leukotriene, receptor (Cysl-T1R) antagonist induces the growth arrest of cancer cells through apoptosis. In this Study, we examined the effects of the CysLT,R antagonist oil cell proliferation in Urological cancer cell lines, including renal cell carcinoma, bladder cancer, prostate cancer and testicular cancer cells. The inhibitory effect of the CysLT,R antagonist on the urological cancer cells was investigated using the MTT assay and flow cytometry. The CysLT(1)R antagonist induced a reduction in cell viability with a half-maximal concentration of growth inhibition in all the urological cancer cell lines, and arrested the growth of the cells through early apoptosis. In conclusion, the Cysl-T1R antagonist may mediate potent anti-proliferative effects against urological cancer cells through early apoptosis, and may therefore serve as a novel therapeutic target in the treatment of urological cancer.

引用

页码：329 / 332

页数：4

共 12 条

[1] Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors [J].

Drazen, J .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) :S233-S237

[2]

Funao K, 2008, MOL MED REP, V1, P185

[3] The role of leukotriene modifiers in the treatment of asthma [J].

Horwitz, RJ ;

McGill, KA ;

Busse, WW .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (05) :1363-1371

[4]

LAFYATIS R, 1989, J IMMUNOL, V143, P1142

[5]

Lynch KR, 1999, NATURE, V399, P789

[6]

Matsuyama M, 2004, INT J MOL MED, V13, P665

[7]

Matsuyama M, 2007, ONCOL REP, V18, P99

[8]

Nielsen CK, 2005, CANCER RES, V65, P732

[9] Leukotrienes induce cell-survival signaling in intestinal epithelial cells [J].

Öhd, JF ;

Wikström, K ;

Sjölander, A .

GASTROENTEROLOGY, 2000, 119 (04) :1007-1018

[10] Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction [J].

Storms, William .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) :2173-2187

← 1 2 →